Lemuel Moye
Overview
Explore the profile of Lemuel Moye including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
652
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mathew S, Lucas K, Sayre S, Bettencourt J, Collins T, Leach D, et al.
Monitor (Assoc Clin Pharmacol)
. 2015 Feb;
28(1):31-36.
PMID: 25648469
No abstract available.
2.
Gee A, Richman S, Durett A, McKenna D, Traverse J, Henry T, et al.
Cytotherapy
. 2010 Jun;
12(5):684-91.
PMID: 20524773
Abstract Background aims. Multicenter cellular therapy clinical trials require the establishment and implementation of standardized cell-processing protocols and associated quality control (QC) mechanisms. The aims here were to develop such...
3.
de Moor J, Moye L, Low M, Rivera E, Singletary S, Fouladi R, et al.
J Soc Integr Oncol
. 2008 Jun;
6(2):59-66.
PMID: 18544285
This study evaluated whether expressive writing (EW) was an effective stress management intervention for breast cancer patients. Women were recruited at the end of neoadjuvant chemotherapy and assigned to write...
4.
Tonelli M, Sacks F, Arnold M, Moye L, Davis B, Pfeffer M
Circulation
. 2008 Jan;
117(2):163-168.
PMID: 18172029
BACKGROUND: Higher levels of red blood cell distribution width (RDW) may be associated with adverse outcomes in patients with heart failure. We examined the association between RDW and the risk...
5.
Hyman D, Pavlik V, Taylor W, Goodrick G, Moye L
Arch Intern Med
. 2007 Jun;
167(11):1152-8.
PMID: 17563023
Background: Many patients in primary care settings present with multiple behavioral risk factors for cardiovascular disease. Research has provided little information on the most effective ways to approach multiple behavior...
6.
Jose P, Skali H, Anavekar N, Tomson C, Krumholz H, Rouleau J, et al.
J Am Soc Nephrol
. 2006 Aug;
17(10):2886-91.
PMID: 16928807
Baseline renal function is a potent independent risk factor for adverse events after acute myocardial infarction (MI). Worsening renal function (WRF) has been shown to influence outcomes in the heart...
7.
Tonelli M, Moye L, Sacks F, Cole T, Curhan G
J Am Soc Nephrol
. 2003 May;
14(6):1605-13.
PMID: 12761262
Limited data suggest that HMG-CoA reductase inhibitors (statins) may slow loss of renal function in individuals with chronic renal insufficiency. This study was conducted to determine whether pravastatin reduced rates...
8.
Tonelli M, Moye L, Sacks F, Kiberd B, Curhan G
Ann Intern Med
. 2003 Jan;
138(2):98-104.
PMID: 12529091
Background: Cardiovascular disease is a common cause of morbidity and death in persons with renal insufficiency. Although 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors (statins) are effective for secondary prevention of cardiovascular...
9.
Solomon S, St John Sutton M, Lamas G, Plappert T, Rouleau J, Skali H, et al.
Circulation
. 2002 Sep;
106(10):1251-5.
PMID: 12208801
Background: Diabetic patients are at increased risk for heart failure (HF) and other adverse events after myocardial infarction (MI). Left ventricular (LV) enlargement after MI is also associated with the...